No amount of lab work prepares a researcher for the moment their science is tested on a real person for the first time. For Dr. Naji Gehchan and the team at @kyverna_us, one of those moments came in 2024, when Marci Pedrazzi McCue became the first person in a U.S. clinical trial to receive an investigational CAR T-cell therapy for the treatment of multiple sclerosis (MS) an approach that resets a patient's own immune cells to target disease. As Dr. Gehchan notes, innovation comes with a responsibility to ensure promising treatments reach the patients who need them most. Marci's courage, combined with the fearless determination of researchers and her medical team, is helping advance knowledge that could shape the future for millions living with MS. That determination – carried by patients and scientists alike – is the #FightofOurLives. Breakthroughs happen when patients and scientists move forward together. Watch Marci's story: fightofourlives.com/stories/…

50 years of biotechnology in 50 seconds 🧬⏱️BIO President & CEO John F. Crowley reflects on a half-century of innovation and looks to what comes next: renewed investment, modernized regulatory pathways, and greater trust in science - all essential to protecting our innovation pipeline and expanding access for patients. #Biotech50

BIO and over 80 other organizations and companies signed a Sept. 14 letter urging Congress to pass a Pandemic and All Hazards Preparedness Act (PAHPA) reauthorization bill. Bio.News outlines BIO's priorities for the legislation: bio.news/national-security/a…

A new U.S. Chamber of Commerce report links strong IP protection directly to higher biotech R&D investment and clinical trial activity worldwide. Read more on Bio.News: bio.news/international/stron…

With just days until sweeping new pharmaceutical tariffs take effect, one thing is clear: the companies least able to absorb the hit are the ones facing the most uncertainty. As BIO President and CEO John F. Crowley warns in @Biocentury, these tariffs would raise costs, impede domestic manufacturing, and divert scarce resources away from the research that drives American innovation. Read more: biocentury.com/article/66083…

Biotech innovators are working every day to turn scientific breakthroughs into new treatments for patients. But too much of the money moving through the health care system is captured by insurers and middlemen instead of helping patients afford the medicines they need - or supporting the next generation of innovation. A simplified system can help ensure savings reach patients, while strengthening the incentives that make continued investment in breakthrough science possible. It’s time to #SimplifyTheSystem: bio.org/simplify-the-system

Congratulations to @UTHRMed on its nearly 700,000-square-foot expansion in Merrimack, New Hampshire. The $47 million investment is expected to bring hundreds of high-paying jobs to the region. Read more: nhbr.com/merrimack-anheuser-…

At #BIOPACE26, BIO's Sarah Alspach will sit down with @KatyGrainger - sepsis survivor, national patient advocate, and @SepsisAlliance board member - for a conversation grounded in BIO's Fight of Our Lives campaign. Their conversation will follow Katy's story and the system she's fighting to improve - defined by the people and breakthroughs changing what's possible. Learn more about the program: pace.bio.org

Shape the conversation at BIO International Convention 2027. Submit your session proposal by October 15: convention.bio.org/program/2…

There was no guarantee the fight would be worth it. Marci took it on anyway… Living with multiple sclerosis (MS), Marci Pedrazzi McCue was the first person in a U.S. clinical trial to receive CAR-T cell therapy for MS - an approach that resets a patient's own immune cells to fight the disease from within. The results were remarkable: zero oligoclonal bands, a key marker doctors use to track MS activity. It was made possible by a clinical trial led by Dr. Jeffrey Dunn at Stanford and a therapy developed by @Kyverna_Tx . Marci didn't take on this fight only for herself, but for the millions living with MS still waiting for hope. This is the #FightofOurLives. Watch Marci's full story: fightofourlives.com/stories/… #Biotech #MultipleSclerosis

Combination vaccines are decades of American biotech innovation, distilled into a single, proven shot. They didn't happen by accident - they're the result of sustained research, rigorous testing, and continuous safety monitoring even after approval. That work is why doctors and parents trust them today. Fewer needles and fewer appointments are the visible benefit - the research behind them is what makes that possible.

Uncertainty over pharmaceutical tariff exemptions is already complicating investment and R&D decisions industry-wide - with implementation two weeks away and no federal guidance yet issued. Read the full story: bio.news/latest-news/with-ph…

As part of a recent staff retreat, BIO employees built bikes that were donated to children through the @ymcadc's 32nd Annual Thingamajig Invention Convention. The program encourages young people to imagine, invent, and problem-solve - and BIO is proud to support an initiative that helps put those values into action. Thank you to the YMCA for the opportunity to give back to our community.

AI-driven analysis of genetic sequences - known as generative genomics - could shorten drug development timelines from years to months, according to biotech and pharma leaders at a BIO 2026 panel. Bio.News breaks down what it will take for researchers to trust the models: bio.news/latest-news/bio-202…

Yesterday, BIO's Michele Oshman and Phyllis Arthur were featured speakers at the inaugural Future of Public Health conference in Washington, D.C., presented by the @RCJAPH in cooperation with @RealClearHealth. Michele, BIO's Chief Patient Advocate and SVP of Alliance Development, joined a panel on prior authorization, examining how the utilization-management process affects patients' access to care their doctors have already prescribed. Phyllis, BIO's Chief of Global Health, joined a panel on the future of U.S. vaccine policy alongside pediatric infectious disease clinicians, ACIP members, and government officials, assessing how U.S. vaccination practice compares with peer nations. A big thank you to the Journal of the Academy of Public Health and RealClearHealth for hosting BIO!

BIO's Chief Patient Advocate, Michele Oshman, moderated a panel on the road to clinical development in women's health at #BIO2026. Bio.News has the discussion, including how researchers are uncovering new insight into how diseases like cardiovascular disease and Alzheimer's present differently in women. Read more: bio.news/latest-news/bio-202…

Life science companies are navigating changing operational needs, new technologies, and an evolving landscape of products and services. BIO Savings Week, September 16–17, brings together BIO Business Solutions® providers to share what they’re seeing across the industry, emerging challenges, and new solutions companies should have on their radar. September 16 | Lab & Business Essentials September 17 | Specialized Business Solutions Attendees will also learn about BIO member-preferred savings and value-added benefits available through the BIO's purchasing program. Register to join us for one day or both: bio-org.zoom.us/webinar/regi…

BIO commented on FDA's Expedited IND Pilot Program, backing its rolling review concept but raising concerns that a required third-party research partner could add delays instead of removing them. Bio.News has the details: bio.news/federal-policy/bio-…

State legislatures wrapped their 2026 sessions with continued activity on prescription drug affordability boards, 340B oversight, vaccine liability, and AI regulation. Bio.News chatted with BIO's Patrick Plues on what he's tracking heading into 2027: bio.news/state-policy/mid-ye…

At #BIOPACE26, experts will examine what it means to usher in 21st century access and affordability, with patient-centric policies that reduce barriers, bureaucracy, and delays - so patients can get the treatment they need, when they need it. View the full agenda: pace.bio.org